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Abstract
Mid-life hypertension and cerebrovascular dysfunction are associated with increased risk of later life dementia, including 
Alzheimer’s disease (AD). The classical renin–angiotensin system (cRAS), a physiological regulator of blood pressure, 
functions independently within the brain and is overactive in AD. cRAS-targeting anti-hypertensive drugs are associated 
with reduced incidence of AD, delayed onset of cognitive decline, and reduced levels of Aβ and tau in both animal models 
and human pathological studies. cRAS activity is moderated by a downstream regulatory RAS pathway (rRAS), which is 
underactive in AD and is strongly associated with pathological hallmarks in human AD, and cognitive decline in animal 
models of CNS disease. We now show that enhancement of brain ACE2 activity, a major effector of rRAS, by intraperitoneal 
administration of diminazene aceturate (DIZE), an established activator of ACE2, lowered hippocampal Aβ and restored 
cognition in mid-aged (13–14-month-old) symptomatic Tg2576 mice. We confirmed that the protective effects of DIZE 
were directly mediated through ACE2 and were associated with reduced hippocampal soluble Aβ42 and IL1-β levels. DIZE 
restored hippocampal MasR levels in conjunction with increased NMDA NR2B and downstream ERK signalling expres-
sion in hippocampal synaptosomes from Tg2576 mice. Chronic (10 weeks) administration of DIZE to pre-symptomatic 
9–10-month-old Tg2576 mice, and acute (10 days) treatment in cognitively impaired 12–13-month-old mice, prevented the 
development of cognitive impairment. Together these data demonstrate that ACE2 enhancement protects against and reverses 
amyloid-related hippocampal pathology and cognitive impairment in a preclinical model of AD.
Keywords Alzheimer’s disease · Renin–angiotensin system · ACE2 · MasR · DIZE · Angiotensin-(1–7)
Introduction
Overactivity of the classical renin–angiotensin system 
(cRAS) within the brain has been implicated in the patho-
genesis of Alzheimer’s disease (AD) (reviewed by [1, 
2]). Elevated ACE1 activity and higher levels of Ang-II 
and the angiotensin-II type 1 receptor (AT1R) have been 
reported in human AD brain tissue [3–6]. Evidence from 
large epidemiological and clinical studies indicate that 
some cRAS-targeting anti-hypertensives, including ACE1 
inhibitors (ACE-Is) and AT1R receptor blockers (ARBs), 
reduce the incidence of AD [7–9], and can prolong the 
conversion to MCI and delay the onset of dementia 
[10–12]. Clinical use of anti-hypertensives is associated 
with improved tau and Aβ indexes in CSF and autopsied 
brain tissue [11, 13, 14]. Insights from animal models indi-
cate that the protective effects of ACE-Is and ARBS are 
associated with anti-inflammatory and anti-oxidative stress 
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mechanisms, in addition to lowering blood pressure and 
improving cerebral blood flow [15–17]. Clinical trials are 
currently underway to determine if cRAS-targeting anti-
hypertensives will have a beneficial effect in patients with 
AD [18, 19].
Activity of the cRAS is counterbalanced by downstream 
regulatory RAS (rRAS) pathways [20, 21], which appear 
to be the dominant RAS pathways in the brain [22, 23]. 
Enzymes such as ACE2 and aminopeptidases-A and -N con-
vert Ang-II (and Ang-III) into smaller bioactive fragments, 
most commonly Ang-1–7 and Ang-IV, reducing Ang-II 
associated cRAS signalling via AT1R. Recent findings show 
reduced CNS activity in the rRAS pathway and that induc-
tion of ACE2, or Ang-(1–7) activation of MasR signalling, 
is neuroprotective against ischaemic stroke and neurogenic 
hypertension in experimental animal models of CNS injury 
[24, 25]. ACE2 overexpression is associated with reduced 
cRAS signalling, including reduced ACE1 activity, Ang-
II level and AT1R expression [26–29] and reduced oxida-
tive stress and neuro inflammation. In a recent comparative 
study, rRAS activation outperformed a prototype cRAS 
blocker in reducing oxidative and inflammatory responses 
in an ischemia/reperfusion mouse model of stroke [30]. 
Activation of downstream rRAS receptors, such as MasR, 
insulin-regulated aminopeptidase (IRAP) and c-MET, which 
are primarily expressed in the hippocampus [31], all induce 
long-term potentiation (LTP) and knockout of MasR disrupts 
object recognition memory in rodents [32, 33] and reviewed 
by [34]. Collectively these data suggest that rRAS activation 
offers protection against many of the pathological disease 
processes associated with cRAS activation that are charac-
teristic in AD but may in addition directly benefit normal 
cognition, through promoting synaptic plasticity processes 
linked to memory.
We have previously shown that there is dysregulation of 
endogenous rRAS activity in postmortem confirmed AD 
brain tissue, which is strongly associated with cRAS over-
activation and disease pathology (Aβ and Tau) [35, 36]. 
Specifically, ACE2 activity, predominantly involved in the 
conversion of Ang-II to Ang-(1–7) [37, 38], was reduced by 
almost 50% in AD cases, which was significantly related to 
Aβ and Tau levels [35]. In an ovariectomised D-galactose 
rodent model of ageing and dementia, enhancement of ACE2 
activity by administration of DIZE reduced brain Aβ pathol-
ogy and improved cognitive performance [39]. We now pre-
sent the first data of the impact of ACE2 enhancement in an 
established transgenic APP mouse model, Tg2576 mice, in 
which the timing and onset of Aβ pathology and behavioural 
abnormalities have been well characterised and recognised 
to model abnormalities in human AD. This study tested the 
hypotheses that enhancement of ACE2, using an established 
ACE2 activator (DIZE), will reduce Aβ-related pathology 
and restore cognitive function in symptomatic aged Tg2576 
mice and prevent the onset of cognitive decline when admin-
istered to pre-symptomatic (younger) Tg2576 mice.
Materials and methods
Animals
A total of 182 male mice were used in this study across 
four separate cohorts (see Table 1). All WTs and Tg2576 
mice within each individual cohort were from the same 
Table 1  Numbers of mice used in each experiment. The age at which mice commenced and finished behavioural assessment and were culled is 
shown
Cohort 1 (30 Day DIZE administration)
WT Vehicle Tg2576 Vehicle Tg2576 DIZE - Total Age at Start Age at End
12 11 9 - 32 13.5 months 15 months
Cohort 2 (30 Day DIZE and DIZE+C16 administration)
WT Vehicle Tg2576 Vehicle Tg2576 DIZE Tg2576 DIZE+C16 Total Age at Start Age at End
21 12 13 11 57 13.5 months 15 months
Cohort 3 (30 Day DIZE administration; Synaptosome Analysis
WT Vehicle Tg2576 Vehicle WT DIZE Tg2576 DIZ Total Age at Start Age at End
7 7 7 7 28 13 months 15 months
Cohort 4 (10-Week and 10-Day administration)
WT Vehicle Tg2576 Vehicle Tg2576 DIZE (10-week) Tg2576 DIZE (10-day) Total Age at Start Age at End
20 16 11 17 64 9 months 12 months
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litters to act as appropriate littermate controls. Mice were 
individually housed due to their aggressive behaviour, as 
previously reported [40, 41]. Tg2576 mice expressing the 
human APP695Swe mutation were maintained on a hybrid 
C57Bl/6 × SJL background [42]. Mice were housed on a 
12-h light–dark cycle. Testing occurred during the light 
period (08:00–19:00). Mice were allowed ad libitum access 
to food and water throughout the duration of the experiment. 
All experiments were conducted in compliance with the UK 
Home Office under the Animal Scientific Procedures Act 
(1986) and EU regulations.
Drugs
Diminazene aceturate (DIZE) was purchased from Santa-
Cruz Biotechnology (CAS 908-54-3). DIZE was freshly 
prepared daily in 0.9% sterile saline to a concentration 
of 50 mg/ml. DIZE was administered to Tg2576 mice at 
15 mg/kg/day by intraperitoneal (i.p.) injection using a BD 
MicroFine™ 0.5-ml insulin syringe. All other mice received 
equivalent volumes of vehicle (saline) injections. This dose 
was based on several previous studies showing that the opti-
mal dose of DIZE in inducing ACE2 activity was 15 mg/kg/
day [39, 43, 44] and a preliminary study of our own across a 
range of DIZE concentrations by IP that confirmed previous 
findings (data not shown).
A competitive ACE2 antagonist, based on the structure 
of a commercially available compound, C16 (MLN4760, 
Merck Millipore) was synthesised according to reported 
procedures [45], and purified by reverse phase flash chro-
matography. Purity and identity were confirmed by 1H and 
13C NMR spectroscopy, polarimetry, high-resolution mass 
spectrometry and HPLC. The compound data were in good 
accordance with the literature and the inhibitor performed 
similar to the commercial inhibitor when tested in vitro 
using recombinant mouse ACE2 (R&D systems) (data not 
shown). The ACE2 inhibitor was co-administered with DIZE 
in relevant experiments, in an identical vehicle as DIZE, at 
25 mg/kg/day, which was the dose most consistently used in 
previous C16 studies [46, 47].
Experimental design
In Experiment 1, we investigated whether DIZE influenced 
cognitive performance and Aβ-related pathology in male 
13–15-month-old Tg2576 mice. An outline of the experi-
mental design is shown in Fig. 1a. Mice from cohort 1 con-
sisted of three groups: WT vehicle (n = 13), Tg2576 vehicle 
(n = 11) and Tg2576 DIZE (n = 11). Prior to group alloca-
tion, all mice were tested on the object-in-place (OiP) task 
(as described below) to establish a baseline of cognitive 
performance and to ensure that the Tg2576 groups had a 
comparable level of performance prior to drug administra-
tion. Following group allocation, all mice were weighed 
and six mice/group were used to assess mean arterial blood 
pressure (MABP) and heart rate (HR) at baseline (see also 
below). A 30-day DIZE/vehicle treatment period then com-
menced. Mice received daily i.p. injections in the morning 
and were rested for at least 1 h before any physiological/
behavioural testing was performed. Mice were weighed and 
MABP and HR measurements were recorded weekly in the 
sub-groups of mice until the end of the treatment period. 
Behavioural assessment was again conducted starting with 
habituation on day 23 of drug treatment followed by the OiP 
task on day 28 and day 30 of treatment. Immediately follow-
ing behavioural assessment at day 30, the mice were culled 
by cervical dislocation and the left and right hippocampi 
and cortices were dissected and snap frozen in liquid nitro-
gen and stored at − 80 °C until processed for downstream 
biochemical and pathological assessment. A total of three 
mice in cohort 1 died during the Experiment 1—one WT 
vehicle and two from the Tg2576 DIZE group (one on day 
2 of administration and the second on day 29). Therefore, 
the final n for the WT vehicle group was n = 12, the Tg2576 
vehicle group remained at n = 11 and the Tg2576 DIZE 
group was n = 9.
In Experiment 2, we aimed to (1) replicate our findings 
from Experiment 1 in a larger independent cohort (cohort 2) 
and (2) determine if the observed protective effects of DIZE 
were specific to ACE2 enhancement. The experimental 
design used identical dosing and behavioural testing meth-
ods as outlined for Experiment 1 (see Fig. 1a). However, in 
this experiment, we included an additional group of mice 
that were co-administered DIZE and C16 (an ACE2 inhibi-
tor) to test the hypothesis that enhanced ACE2 activity was 
required for the protective effects of DIZE. A total of four 
mice died in cohort 2 (two mice administered DIZE and two 
administered DIZE + C16). Final group numbers in cohort 
2 were, therefore, as follows: WT vehicle (n = 22), Tg2576 
vehicle (n = 11), Tg2576 DIZE (n = 12), Tg2576 DIZE + C16 
(n = 11). Cohorts 1 (Experiment 1) and 2 (Experiment 2) 
were used for discovery and replication studies, respectively, 
to test and verify the behavioural changes independently but 
brain tissue was collected and combined from both cohorts, 
given the identical experimental dosages and design, to 
allow for meaningful statistically powered biochemical 
assessment of changes in ACE2, Aβ, cytokines, and mark-
ers of astrocyte, microglial and vascular function.
In Experiment 3, we studied a separate cohort of mice 
(cohort 3) consisting of four groups: WT vehicle (n = 7), 
WT DIZE (n = 7), Tg2576 vehicle (n = 7) and Tg2576 DIZE 
(n = 7) (all 13–15 months old). The addition of WT DIZE 
group was designed to assess if DIZE affected WT mice 
behaviour and biochemistry in the same way as Tg2576 
mice. The experimental procedure replicated that of 
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Fig. 1  Schematic representation of the experimental design in a for 
Experiments 1, 2 and 3 and b for Experiment 4. a Male mice between 
13 and 14 months of age were subject to pre-drug assessment in the 
object-in-place (OiP)-associative recognition memory task to estab-
lish a baseline measurement. Mice were then randomly assigned into 
groups to ensure that there was no significant difference in behaviour 
prior to treatment. All WT mice were administered vehicle (saline) 
only. In Experiment 1, Tg2576 mice were administered either vehicle 
(saline) or DIZE (15 mg/kg/day) for 30 days. In Experiment 2, a third 
Tg2576 group was added that was administered DIZE + C16 (25 mg/
kg/day) for 30 days. In Experiment 3, both WT and Tg2576 groups 
were administered vehicle or DIZE. In each experiment, on day 23 
of treatment, post-drug assessment commenced with habituation and 
testing was performed on days 28 and 30. All mice were culled and 
brains were dissected on day 30 immediately following post-testing 
and underwent pathological and biochemical assessment. b Mice 
underwent pre-drug assessment at 9–10 months of age and all mice 
were found to be asymptomatic. The mice were then divided into four 
groups: WT vehicle, Tg2576 vehicle, Tg2576 DIZE (chronic) and 
Tg2576 DIZE (acute). Tg2576 groups were allocated based on OiP 
performance so that all groups showed comparable levels of contact 
time and DR score performance. All groups except Tg2576 DIZE 
acute commenced IP DIZE treatment (15  mg/kg/day) or vehicle for 
10 weeks. At 8 days prior to the final two test days at 12–13 months 
of age, DIZE acute mice received drug treatment daily for 10  days 
(15 mg/kg/day). Tg2576 mice had previously been shown to be cog-
nitively impaired at 12–13  months of age in Experiments 1 and 2. 
Mice across all four groups were re-tested at 12–13 months of age. 
At the end of the study, after all mice had undergone OiP testing, they 
were culled immediately and underwent pathological and biochemi-
cal assessments
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Experiments 1 and 2. Upon completion of this study, mice 
brains were either snap frozen for biochemical assessment 
or processed for IHC and IF analyses.
In Experiment 4, we used a 4th group of mice (cohort 4) 
to investigate if long-term (10 weeks) DIZE administration 
(Tg-DIZE chronic) could protect against the development 
of Aβ pathology and cognitive impairment when adminis-
tered to pre-symptomatic younger mice aged 9–10 months. 
To validate and extend our observations on the beneficial 
effects of DIZE in aged (symptomatic) Tg2576 mice, we 
compared the chronic treated (10 weeks) condition with 
a group that received DIZE acutely for 10 days (Tg-DIZE 
acute) at 12–13 months of age (n = 17) immediately prior to 
behavioural testing and tissue collection. The experimental 
procedure is summarised in Fig. 1b. We studied WT vehi-
cle (n = 20), Tg2576 vehicle (n = 16) and Tg-DIZE chronic 
(n = 11) or Tg-DIZE (n = 17).
Behavioural assessment
All mice were tested on the OiP task as previously described 
[48, 49]. A detailed description of the OiP task is presented 
in Supplementary Fig. 1, online resource. Briefly, prior to 
testing associative recognition memory, animals were habit-
uated to the arena. Mice were allowed to explore the arena 
freely for 10 min on day 1 and day 2. Mice were then further 
habituated for two consecutive days to the arena contain-
ing four different objects for 10 min each day. Each object 
was approximately 15 cm from the walls of the arena and 
25 cm apart from each other. This arrangement remained 
constant throughout the study. A different set of objects was 
used each day and across both time points tested. No sets 
of objects were re-used during habituation or testing. Each 
mouse received two rounds of behavioural testing; each test 
was separated by 48 h. The group of objects used and spe-
cific pair of objects that underwent a location switch and 
their order across days were counterbalanced within and 
between groups.
Time spent exploring the objects was recorded in both 
sample and test phases. Object exploration was defined 
according to the methods described previously by Ennaceur 
and Delacour (1988). In brief, object contact was defined as 
when an animal was within a 2 cm radius of the object and 
directly facing, sniffing, gnawing, but not climbing or sitting 
on, the objects. A discrimination ratio (DR) was used to pro-
vide an index of the mouse’s discrimination performance in 
the test phase that was independent of individual differences 
in object contact times; this was calculated as the time spent 
exploring objects in novel locations/the time spent explor-
ing all objects. All reported contact times and DR scores 
were averaged across the two trials. We mitigated against 
the potential effects of repeat testing in our study by coun-
terbalancing across object sets and switching the location of 
objects within and between groups. All objects were cleaned 
before each phase of testing to reduce the use of odour cues 
introduced from handling the objects.
Blood pressure measurement
Our aim was to use a dose of DIZE that influenced ACE2 
activity but did not change blood pressure. The effect of 
DIZE (15 mg/kg/day) on MABP and HR was, therefore, 
assessed at weekly intervals over the entire course of the 
study in Experiment 1. Measurements were taken prior to 
DIZE treatment to determine a baseline MABP and then at 
weekly intervals until the end of the study. Six mice from 
each treatment group were habituated to the apparatus (Har-
vard Apparatus) and used throughout the study. To habit-
uate animals for MABP and HR recordings, each mouse 
was given a 15-min trial/day for 4 days. Mice were placed 
in a mouse holder (Part no. 76-0184) underneath a heat-
ing unit (Part no.76-0178) in a dark room. The tail cuff and 
pulse transducer (Part no. 76-0432) were placed around the 
mouse’s tail and inflated 7–8 times/session. Following habit-
uation, each mouse was placed in the holding unit and given 
2–3 min to adapt to the dark room and warmth from the heat-
ing device, after which the tail cuff was inflated and MABP 
and HR was recorded from the blood pressure recording unit 
(Part no. 76-0173). Three recordings (that were averaged) 
were taken per mouse. Mice were then removed from the 
holding unit and returned to home-cages, after which the 
holding units were wiped clean with 70% ethanol wipes and 
allowed to dry thoroughly between mice, to prevent stress 
that may have been caused from residual scents from other 
males.
Biochemical measurements of markers of disease 
pathology
Immediately following behavioural testing, mice were culled 
by cervical dislocation and their brains were removed and 
dissected. In Experiments 1, 2 and 4, both hemispheres were 
dissected into cortex, hippocampus and frontal cortex and 
snap frozen at − 80 °C until protein extraction as previ-
ously described [51]. In Experiment 3, the left hemisphere 
was dissected as above, snap frozen, and used for synapto-
some extraction (see below). The contralateral hemisphere 
was fixed in 4%PFA in 0.1 M PBS for 12 h before being 
transferred to 25% sucrose in PBS for 48 h. Brains were 
then sliced using a vibratome and stored in cryoprotectant 
as previously described [52].
Synaptosome extraction
Synaptosome extractions were performed using Syn-PER™ 
synaptic protein extraction reagent (ThermoFisher, UK). 
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Western blotting was performed using standard methods as 
described previously [51]. Briefly, after protein quantifica-
tion, 20 μg protein/sample was resolved on either a 10 or 
7.5% polyacrylamide gel and detected with the relevant anti-
body (NR2B, pY1472-NR2B (Millipore), GluA1, pSer845 
GluA1, PSD95 (Abcam), total ERK, phospho-ERK (Cell 
Signalling Technologies), NR1 (BD Biosciences), Total Tau 
(DAKO), PHF1 (p-Tau Ser396/404; a generous gift from P. 
Davies) and β-actin (Sigma).
Amyloid‑β ELISA measurements
Soluble and insoluble fractions were extracted from right 
hippocampus and right cortex as previously described [53]. 
Briefly, brain samples of each mouse were homogenised in 
2% sodium dodecyl sulphate (SDS) using a Precellys 24‐
Dual (Bertin technologies). Homogenate was centrifuged 
at 28,300 rpm for 1 h at 4 °C. The supernatant was care-
fully removed and stored at – 20 °C for later analysis as 
the “soluble” fraction. The insoluble pellet was further dis-
solved in 70% formic acid. Samples were centrifuged again 
at 28,300 rpm for 1 h at 4 °C. The supernatant was carefully 
removed and added 1:20 to a neutralising buffer (1 M Tris, 
0.5 M  Na2HPO4, pH 11) and stored at − 20 °C for subse-
quent analysis.
Enzyme-linked immunosorbent assay (ELISA) kits spe-
cific for human Aβ40 and Aβ42 (Invitrogen:#KHB3482 
and #KHB3441) and Aβ43 (Tecan: RE59711) were used 
to quantify soluble and insoluble Aβ species according to 
the manufacturer’s instructions. Results were expressed as 
picograms (pg) per milligram (mg) of tissue. The mean from 
duplicate measurements are presented.
ACE1 and ACE2 enzyme activity measurements
To quantify the enzyme activity of ACE1 and ACE2, we 
used established fluorogenic assays that have previously 
been described [4, 5, 35, 54]. Brain tissue samples from the 
left hippocampus and left cortex were dissected and homog-
enised in 1% SDS lysis buffer using an automated Precellys 
tissue homogeniser. ACE1 and ACE2 activities were quanti-
fied using an ACE1 fluorogenic peptide Abz-FRK(Dnp)-P 
(Enzo Life Sciences) in the presence/absence of captopril 
(Enzo) or an ACE2 substrate peptide Mca-APK(Dnp) in the 
presence/absence of MLN4760 (Millipore). Specific enzyme 
activity was calculated by subtracting the fluorescence in 
the presence of the specific inhibitor from total fluorescence 
without inhibition.
ACE2 protein level measurement
Total protein levels of ACE2 were measured in the right 
hippocampus by ELISA according to the manufacturer’s 
instructions (Abcam: ab213843).
Angiotensin‑I, ‑II and ‑(1–7) measurement
Levels of Ang-I, Ang-II, Ang-(1–7) were measured in hip-
pocampal homogenates prepared in 1% SDS using in-house 
direct ELISA’s, as previously described for the quantification 
of peptides in human postmortem brain tissue and CSF [4, 5, 
35, 36, 54]. In brief, serial dilutions of recombinant Ang-I, 
Ang-II or Ang-(1–7) (5000–78.125 pg/ml) (Abcam, Cam-
bridge, UK), and mouse brain extracts (diluted 1 in 20 in 
PBS) were coated on a Nunc Maxisorp 96-well plate (Ther-
moFisher Scientific, Waltham, MA, USA) for 2 h at room 
temperature on a plate shaker (300 rpm), washed, and incu-
bated with biotinylated detection antibodies [biotinylated 
anti-Ang-I (diluted 1 in 100 in PBS); biotinylated anti-Ang-
II (diluted 1 in 500 in PBS) or biotinylated anti-Ang-(1–7) 
(diluted 1 in 100 in PBS) (all from Cloud-Clone, Wuhan, 
China)] for another 2 h with shaking. After washing and 
incubation with streptavidin:HRP (diluted 1 in 200 in 0.1% 
PBS:Tween-20) (R&D systems) for 20 min, the plates were 
washed and incubated with TMB substrate (R&D systems). 
The reaction was stopped after 20 min and absorbance was 
read at 450 nM using a FLUOstar OPTIMA plate reader 
(BMG Labtech, Aylesbury, BUCKS, UK). Samples were 
measured in duplicate and interpolated from the serial dilu-
tion of recombinant protein.
Cytokine measurements
ELISA kits specific for mouse interleukin (IL)-1β, IL-6 and 
IL-10 and TNF-α (R&D Systems: DY401, DY406, DY417, 
DY410) were used to quantify cytokine levels in hippocam-
pal soluble sample extracts. Results were expressed as pg/
mg. Means from duplicate readings are presented.
Microglial (CD68 and IBA1) and astrocyte (GFAP) ELISA
The level of an astrocytic activation marker (GFAP) and 
two independent microglial markers (IBA1 and CD68) were 
measured in hippocampal samples homogenised in 1% SDS 
buffer using commercial ELISA kits following the manu-
facturer’s protocols: GFAP (samples diluted 1 in 2000) (Cat 
no: SEA068Mu), IBA1 (samples diluted 1:200 in PBS) (Cat 
no. SEC288Mu) (Cloud Clone, Wuhan, China) and CD68 
(samples diluted 1 in 650 in PBS) (Cat no. OKEH03503, 
Aviva Systems Biology, San Diego, USA).
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Vascular markers of tissue oxygenation and BBB 
leakiness
The level of VEGF was measured in hippocampal lysates 
diluted 1 in 40 in PBS using a commercially available ELISA 
kit (Cat no. DY493, R&D systems) (MA, USA). The ratio 
of MAG:PLP is a marker of tissue oxygenation previously 
developed in studies using human postmortem brain tissue 
[55, 56]. MAG was measured in hippocampal lysates diluted 
1 in 650 in PBS using an in-house direct ELISA that showed 
species cross-reactivity in mice as previously described [55, 
57]. PLP concentration was measured in hippocampal sam-
ples diluted 4 in 100 in PBS using a commercially available 
sandwich ELISA following the manufacturer’s instructions 
(Aviva Biological Systems, San Diego, USA).
Immunofluorescent labelling
Brains hemispheres were fixed in 4% paraformaldehyde in 
0.1 M PBS/PFA for 12 h at room temperature. Brains were 
then transferred to 25% reagent-grade sucrose in 0.1 M PBS. 
Each brain remained in sucrose until sinking, indicating it 
was fully saturated (approximately 48 h), and was then sliced 
using a vibratome. 40-μm coronal sections of hippocampus 
were stored at − 20 C in an ethylene–glycol-based cryopro-
tectant (Sigma, UK) until they were used for immunohisto-
chemical analysis.
Parenchymal Aβ imaging
Sections were washed in 3 × 5-min changes of PBS and 
3 × 5-min washes in distilled water before being incubated 
for 10  min in formic acid. Sections were then washed 
3 × 5 min in distilled water and equilibrated in PBS before 
being blocked for 20 min in 5% PBS/donkey serum (Sigma-
Aldrich, Dorset, UK). Sections were incubated at 4°C over-
night with mouse anti-human Aβ (4G8) at 1 in 250 in PBS 
(Biolegend, San Diego, CA, USA). Sections were washed 
3 × 5 min in PBS and incubated at room temperature for 1 h 
with Alexa Fluor 488 donkey anti-mouse (ThermoFisher 
UK) at 1 in 500 in PBS. Sections were washed 3 × 5 min in 
PBS and mounted using Vectashield mounting medium with 
DAPI (Vector Labs, Peterborough, UK).
MasR immunofluorescent labelling
Sections were washed in 3 × 5-min changes of PBS and 
blocked for 20 min in 5% PBS/donkey or goat serum (Sigma-
Aldrich, Dorset, UK). Sections were incubated at 4 C over-
night with rabbit anti-MasR (1:100) (Cat no. AAR-013) 
(Alomone Labs, Tel Aviv, Israel). Sections were washed 
3 × 5 min in PBS and incubated at room temperature for 1 h 
(1 in 500 in PBS) with Alexa Flour 488 donkey anti-rabbit (1 
in 500 in PBS) (ThermoFisher, UK). Sections were washed 
3 × 5 min and mounted using Vectashield mounting medium 
with DAPI (Vector Labs, Peterborough, UK).
GFAP immunolabelling of reactive astrocytes
Sections were washed in 3 × 5-min changes of PBS and 
blocked for 20 min in 5% PBS/goat serum (Sigma-Aldrich, 
Dorset, UK). Sections were incubated at 4°C overnight with 
chicken anti-GFAP (1:100) (Cat no. abs4674) (Abcam, Cam-
bridge, UK). Sections were washed 3 × 5 min in PBS and 
incubated at room temperature for 1 h with Alexa Fluor 594 
goat anti-chicken (1 in 500 in PBS) (ThermoFisher, UK). 
Sections were washed 3 × 5 min and mounted using Vectash-
ield mounting medium with DAPI (Vector Labs, Peterbor-
ough, UK).
Statistical analysis
All statistical analyses were performed using IBM SPSS 
statistics (version 25). The behavioural data conformed to 
the assumptions of analysis of variance (ANOVA) and were 
analysed using a mixed measures design. Significant inter-
actions were assessed using tests for simple main effects 
with Bonferroni correction. Western blot data were ana-
lysed using one-way ANOVA followed by Tukey’s post 
hoc analysis. ELISA data were analysed using either an 
independent-samples t test or one-way ANOVA with post 
hoc Tukey comparisons. All data were subject to Levene’s 
and Shapiro–Wilks tests for data normality prior to analy-
sis. Appropriate transformations were carried out when 
necessary. Data generated from ELISA assays were quanti-
fied by comparing data to standard curves from each plate 
using GraphPad  Prism®7 and normalised to total protein 
concentration.
Results
DIZE reverses associative recognition memory 
deficits and reduces Aβ pathology in aged Tg2576 
mice
In Experiment 1, WT and Tg2576 mice underwent OiP 
testing. Contact time data were converted to discrimina-
tion ratio (DR) scores (for a full description of OiP object 
contact times see Supplementary Table 1, online resource). 
Tests for simple main effects revealed that prior to DIZE 
administration, both Tg2576 vehicle (Tg-V) and Tg2576 
DIZE (Tg-DIZE) mice did not differ significantly but were 
both impaired compared to WT vehicle (WT-V) controls 
(p = 0.0001 and 0.001, respectively) (Fig.  2a). Follow-
ing the 30-day treatment period, Tg-V remained impaired 
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compared to WT-V mice (p = 0.0001). In contrast, Tg-DIZE 
mice performed comparably to WT-V mice (p = 1.0) and sig-
nificantly better than Tg-V mice (p = 0.0001). The Tg-DIZE 
group showed no overall change in physiological param-
eters, including body weight, MABP and HR compared to 
all groups (Supplementary Fig. 2, online resource).
Hippocampal parenchymal Aβ plaque load was visualised 
using 4G8 immunofluorescent labelling and appeared to be 
lower in Tg-DIZE mice compared to Tg vehicle (Supple-
mentary Fig. 3, online resource). To confirm our immuno-
histochemical observations, we measured insoluble Aβ40, 
Aβ42, and Aβ43 (an early-depositing and highly amyloido-
genic seed that is cleaved by ACE2), in hippocampal extracts 
(Fig. 2c, d). Insoluble Aβ42 (t(18) = 2.16, p = 0.044) and 
Aβ43 (t(18) = 2.22, p = 0.04) were significantly reduced 
in the hippocampus of Tg-DIZE compared to Tg-V mice. 
Insoluble Aβ40 level was not statistically different between 
groups although the absolute levels were numerically lower 
in Tg-DIZE mice (t(18) = 0.89, p = 0.39).
Hippocampal ACE2 enzyme activity was significantly 
different between groups (F(2, 30) = 5.49, p = 0.01) and 
post hoc Tukey analysis revealed significantly elevated 
ACE2 activity in Tg-DIZE mice compared to WT-V and 
Tg-V mice (p = 0.028 and p = 0.013, respectively) (Fig. 2e). 
Hippocampal ACE2 protein level was also significantly 
different between groups (F(2, 30) = 3.35, p = 0.049) and 
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Fig. 2  Improved associative recognition memory and reduced Aβ 
pathology in Tg2576 mice following peripheral administration of 
DIZE. a Following 30-day IP administration of DIZE (15  mg/kg/
day), associative recognition memory, tested using the object-in-
place (OiP) task, was significantly improved in Tg-DIZE mice (n = 9) 
compared to pre-DIZE scores (+++p < 0.001). Tg DIZE mice also 
performed significantly better than Tg vehicle mice (###p < 0.001; 
n = 11). Tg vehicle mice were impaired compared to WT vehicle mice 
(***p < 0.001; n = 12), whilst Tg-DIZE mice showed a comparable 
performance level to WT mice, p > 0.1. b–d Hippocampal insoluble 
Aβ40, Aβ42 and Aβ43 concentration was measured by sandwich 
ELISA. Insoluble Aβ42 and Aβ43 levels were significantly reduced 
in the hippocampus in Tg-DIZE compared to Tg-V mice (*ps < 0.05) 
whereas Aβ40 was unchanged. e Hippocampal ACE2 activity, quanti-
fied using a FRET enzyme activity assay, was significantly elevated 
in the hippocampus of Tg DIZE compared to WT vehicle (*p < 0.05) 
and Tg vehicle  (p# < 0.05) mice. f Hippocampal ACE2 level, meas-
ured by ELISA, was lower in Tg vehicle compared to WT vehicle 
mice (p* < 0.05); no statistically significant difference was observed 
between WT vehicle and Tg DIZE mice (p > 0.05). Behavioural data 
were analysed using mixed measures ANOVA. Significant interac-
tions were further analysed by tests for simple main effects with Bon-
ferroni corrections for multiple comparisons. Amyloid analysis was 
performed using independent-samples t test. ACE2 analysis was per-
formed using one-way ANOVA with post hoc Tukey analysis. Error 
bars represent the standard error of the mean (SEM)
Acta Neuropathologica 
1 3
post hoc analysis revealed a significant reduction in ACE2 
protein level in Tg-V mice compared to WT-V (p = 0.039) 
but no significant difference between WT-V and Tg-DIZE 
(p = 0.56) (Fig. 2f).
DIZE‑mediated restoration of associative 
recognition memory in Tg2576 mice is mediated 
specifically through ACE2 enhancement 
and is associated with reduced hippocampal soluble 
Aβ42
In Experiment 2, we replicated our findings in Experiment 
1 in a second cohort (cohort 2) whilst testing the hypothesis 
that the effects of DIZE on memory were mediated specifi-
cally through enhancing ACE2 activity. An additional group 
of Tg-DIZE mice was co-administered with DIZE + C16 
(C16 is an ACE2 antagonist). Contact time data are pre-
sented in Supplementary Table 2, online resource. Analy-
sis of OiP discrimination ratios (Fig. 3a) confirmed our 
findings in Experiment 1. Tg-V (p = 0.001) and Tg-DIZE 
(p = 0.001) mice were impaired compared to WT-V mice at 
baseline (pre-treatment). Following 30 days of treatment, 
Tg-V remained cognitively impaired compared to WT mice 
(p = 0.001) but memory performance in Tg-DIZE mice 
was significantly improved and comparable to WT-V mice. 
Importantly, the beneficial effect of DIZE was abolished in 
Tg-DIZE + C16 mice compared to Tg-V mice (p = 0.757) 
(Fig. 3a). Furthermore, Tg-DIZE mice showed better OiP 
performance compared to Tg-V mice (p = 0.001) and Tg-
DIZE + C16 mice (p = 0.001).
As for Experiment 1, DIZE significantly altered hip-
pocampal ACE2 activity (F(3, 83) = 6.42, p = 0.0001), 
which was increased in Tg-DIZE mice compared to WT-V 
(p = 0.003) and Tg-V mice (p = 0.001) (Fig. 3b). No change 
in ACE2 activity was observed in Tg-DIZE + C16 mice com-
pared to either WT-V or Tg-V group (ps > 0.05). Although 
hippocampal ACE1 activity was numerically reduced in Tg-
DIZE mice compared to Tg-V mice, it did not reach conven-
tional levels of statistical significance (p > 0.05). However, 
the ratio of ACE2:ACE1 was significantly increased in Tg-
DIZE mice compared to Tg-V mice (p < 0.01).
Hippocampal insoluble Aβ42 and Aβ43 levels were both 
significantly reduced in Tg-DIZE mice compared to Tg-V 
mice (p = 0.010 and p = 0.009, respectively). Hippocampal 
insoluble Aβ42 and Aβ43 levels also remained significantly 
lower in Tg-DIZE + C16 mice (p = 0.0018 and p = 0.002, 
respectively) compared to Tg-V mice (Fig. 3c). The same 
trend was observed for insoluble Aβ40 but did not reach 
statistical significance F(2, 53) = 3.026, p = 0.057 (Fig. 3c). 
All species of soluble Aβ levels were numerically lower 
but not significantly altered in Tg-DIZE mice compared 
to Tg-V (Fig. 3c) (a detailed breakdown of the percentage 
change in Aβ species across experimental groups is shown 
in Supplementary Table 5, online resource). Soluble Aβ42 
was, however, significantly higher in the Tg-DIZE + C16 
mice compared to the Tg-DIZE mice (p = 0.0037) (Fig. 3c).
DIZE‑associated cognitive improvement 
is associated with restored Mas receptor expression 
and enhanced glutamate receptor signalling 
in hippocampal synaptosomes
In Experiment 3, we again confirmed DIZE-mediated 
improvement in OiP DR scores in Tg-DIZE mice in a sepa-
rate cohort of mice (cohort 3) (Fig. 4a) (a detailed assessment 
of contact time and DR scores is shown in Supplementary 
Table 3, online resource). MasR was abundantly expressed 
in the hippocampus, specifically in the dentate gyrus and 
subiculum (Supplementary Fig. 4a, online resource) and 
appeared to be reduced in Tg-V mice compared to WT-V 
mice (Supplementary Fig. 4b, online resource). We were 
unable to quantify IF-labelling but MasR level measured 
by ELISA was reduced in Tg-2576 compared to WT mice 
(p < 0.05) (Supplementary Fig. 4c, online resource). MasR 
expression appeared to be increased in Tg-DIZE compared 
to Tg-V mice in hippocampal synaptosomes assessed by 
western blot (Fig. 4b). On analysis, a significant group 
effect was observed in the level of MasR expression, (F(3, 
27) = 3.55, p = 0.029). Post hoc Tukey analysis revealed that 
MasR level was significantly increased in Tg-DIZE mice 
compared to Tg-V mice (p = 0.041) (Fig. 4c). In contrast, 
the level of the insulin-regulated aminopeptidase receptor 
(IRAP) (also involved in downstream rRAS signalling) was 
unchanged across groups (F(3, 27) = 1.99, p = 0.14).
In hippocampal synaptosomal extracts, the ratio of phos-
phorylated NR2B to total NR2B was altered between groups 
F(3, 27) = 5.23, p = 0.006 and post hoc Tukey analysis 
revealed that in Tg-DIZE, the ratio was increased compared 
to Tg-V mice (p = 0.012) and also in WT-DIZE compared 
to Tg-V mice (p = 0.011) (Fig. 4e). No significant change 
was observed in total levels of GluA1 or GluA1 phosphoryl-
ated at regulatory Ser845 (maximal effect, F(3, 27) = 1.35, 
p = 0.28 (pGluA1), and total levels of PSD95 were 
unchanged F(3, 27) = 0.49, p = 0.70 (Fig. 4f). In addition, 
the level of phosphorylated ERK was significantly altered, 
F(3, 27) = 8.59, p = 0.001. Post hoc Tukey analysis showed 
increased phosphorylated ERK in both Tg-DIZE (p = 0.001) 
and WT-DIZE mice (p = 0.032) compared to respective vehi-
cle controls; in contrast, total ERK was unchanged across 
groups, F(3, 27) = 0.36, p = 0.79 (Fig. 4d) (full blots of all 
samples analysed are shown in Supplementary Fig. 5, online 
resource).
Given that tau has been shown to play a role in learning 
and is commonly hyperphosphorylated in AD [58, 59], we 
further measured levels of tau phosphorylation in hippocam-
pal synaptosomes. However, no significant differences were 
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observed between WT and Tg2576 mice, with or without 
the administration of DIZE, when comparing total levels 
of tau F(3, 20) = 0.70, p = 0.56 or tau phosphorylated at 
Ser396/404, F(3, 20) = 1.12, p = 0.37 (Supplementary Fig. 6, 
online resource). This may be indicative of a lack of reported 
tau changes in Tg2576 mice at this age and future studies 
Fig. 3  DIZE-mediated restoration of the recognition associative 
memory deficit in Tg2576 mice is mediated by enhanced ACE2 and 
is associated with reduced soluble Aβ42. a Associative recogni-
tion memory was impaired in Tg vehicle mice (n = 12) compared to 
WT vehicle mice (n = 21) (***p < 0.001) and Tg2576 DIZE-admin-
istered mice (n = 13) (^^^p < 0.001). DIZE improved the cognitive 
performance of Tg2576 mice compared to pre-DIZE administra-
tion performance (•••p < 0.001). Co-administration of DIZE + C16 
in Tg2576 mice (n = 11) prevented the improvement compared to 
pre-administration performance (p > 0.05). DIZE + C16 mice were 
also impaired compared to WT vehicle (***p < 0.001) and Tg2576 
DIZE mice (+++p < 0.001). b Hippocampal ACE2 activity was 
increased in Tg2576 DIZE-administered mice (n = 22) compared to 
WT vehicle (n = 33) (**p < 0.01) and Tg2576 vehicle mice (n = 23) 
(###p < 0.001; n = 23). Although numerically reduced, no differ-
ence was reported in ACE2 activity in Tg2576 mice co-administered 
DIZE + C16 (p > 0.05; n = 11). There was no significant difference in 
ACE1 activity across groups but the ratio of ACE2:ACE1 was sig-
nificantly elevated in Tg2576 DIZE mice compared to Tg2576 vehi-
cle mice (p < 0.01). These changes were not apparent in Tg2576 mice 
co-administered DIZE and C16, p > 0.05. c Soluble and insoluble 
levels of Aβ40, Aβ42 and Aβ43, were measured by ELISA. Soluble 
Aβ42 was significantly lower in Tg2576 DIZE mice compared to 
mice co-administered DIZE + C16 (*p < 0.05). Insoluble Aβ42 and 
43 was significantly reduced in both Tg2576 DIZE mice and Tg2576 
mice co-administered DIZE + C16. Insoluble Aβ40 was unchanged 
between Tg-DIZE and Tg-DIZE + C16 mice. Behavioural data were 
analysed using mixed measures ANOVA. Significant interactions 
were further analysed by tests for simple main effects with Bonferroni 
corrections for multiple comparisons. ACE2 and Aβ analysis was per-
formed using one-way ANOVA with post hoc Tukey analysis. Error 
bars represent the SEM
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should focus on tau changes in older Tg2576 mice and/or 
more specifically in rodent transgenic tau models.
ACE2‑mediated improvement in associative 
recognition memory is related to reduced 
inflammatory (IL‑1β) but not to markers 
of astrocyte, microglial or vascular function
Hippocampal IL-1β level was significantly altered between 
groups (F(3, 87) = 5.292, p = 0.002) and was significantly 
increased in Tg-V mice compared to WT control (p = 0.018) 
and significantly reduced in Tg-DIZE mice compared to 
Tg-V mice (p = 0.015) (Fig. 5a) (data was obtained from 
animals in Experiments 1 and 2). Hippocampal IL-1β level 
in Tg-DIZE + C16 mice was comparable to Tg-V mice 
(p = 1.0) indicating that the reduction in hippocampal IL-1β 
in Tg-DIZE mice was specifically related to enhanced ACE2 
activity. No significant changes were observed in total lev-
els of hippocampal IL6 (F(3, 87) = 2.470, p = 0.067), IL10 
(F(3, 87) = 2.053, p = 0.113), or TNFα (F(3, 87) = 1.555, 
p = 0.206) in Tg2576 mice (Fig. 5a).
Fig. 4  DIZE-mediated restoration of associative recognition memory 
in Tg2576 mice is associated with restored MasR expression and 
evidence of enhanced NMDA NR2B subunit glutamate signalling. 
a Tg2576 vehicle mice (n = 7) were impaired compared to both WT 
vehicle (*p < 0.05; n = 7) and WT DIZE mice (##p < 0.01; n = 7). 
However, Tg2576 mice administered DIZE (n = 7) showed compara-
ble DR scores to both WT groups, ps > 0.05. b Representative west-
ern blot images showing altered levels of RAS receptor and markers 
of glutamate-mediated LTP signalling in synaptosome-enriched frac-
tions from the hippocampus. c MasR level was significantly increased 
in Tg2576 DIZE mice compared to Tg2576 vehicle (*p < 0.05) 
whereas IRAP level remained unchanged. d To indicate changes in 
synaptic signalling, ERK and phospho-ERK were also probed for 
in hippocampal synaptosomes. No changes in total levels of ERK 
were reported (p > 0.05). However, when phosphorylated ERK was 
normalised to total ERK, there was a significant increase in p-ERK 
in Tg2576 DIZE mice compared to WT vehicle mice (##p < 0.01). 
There was also an increase in p-ERK in WT DIZE mice (*p < 0.05) 
and Tg2576 DIZE mice (***p < 0.001) compared to WT-V. e Total 
levels of NR2B were unchanged across groups (p > 0.05) but the 
ratio of phosphorylated Y1472 NR2B:total NR2B was significantly 
increased in WT DIZE and Tg2576 DIZE compared to Tg2576 vehi-
cle control mice, respectively (*ps < 0.05). f No overall change was 
observed for the post-synaptic marker, PSD95, GluA1 or the ratio of 
pSer845:GluA1 (ps > 0.05). All data were analysed using one-way 
ANOVA with post hoc Tukey analysis. Error bars represent the SEM
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Hippocampal reactive astrocytes were immuno-fluores-
cently labelled with GFAP in the hippocampus and inspec-
tion of the sections suggested that they were more abun-
dantly expressed in Tg-V and Tg-DIZE mice compared to 
WT-V mice (Fig. 5b). Our observations were confirmed by 
ELISA measurements that showed alterations in GFAP level 
across groups (F(3, 54) = 2.055, p = 0.012) with post hoc 
analysis revealing that GFAP was significantly increased 
in all Tg groups compared to WT-V: Tg-V (p = 0.004); Tg-
DIZE (p = 0.001) and Tg-DIZE + C16 (p = 0.015)) (Fig. 5b). 
We measured the level of two independent markers of micro-
glia, IBA1 and CD68, in hippocampal homogenates and 
found no significant difference between Tg2576 and WT 
mice, or in the treated Tg mice group (ps > 0.05; Fig. 5c, d).
Fig. 5  ACE2-mediated restoration of associative recognition memory 
is associated with reduced IL-1β but not astrocytic or microglial acti-
vation. a Hippocampal IL-1β level, measured by sandwich ELISA, 
was significantly increased in Tg2576 vehicle mice (n = 22) com-
pared to WT vehicle (n = 34) (*p < 0.05) and IL-1β was significantly 
reduced in Tg2576 DIZE mice (n = 21) compared to Tg vehicle mice 
(#p < 0.05). IL1-β was not statistically different, however, between 
Tg vehicle and Tg2576 mice co-administered with DIZE + C16 
(n = 11) (ps > 0.05). No overall change was observed in the level of 
IL6, IL10 or TNFα between groups (ps > 0.05). b Representative 
images of GFAP-positive astrocytes within the hippocampus in WT, 
Tg-V and Tg-DIZE mice. GFAP level, measured by ELISA, was sig-
nificantly increased in Tg2576 vehicle mice (p < 0.01), Tg2576 DIZE 
(p < 0.001) and Tg2576 DIZE + C16 mice (p < 0.05) compared to WT 
vehicle. c, d Two independent microglial markers were measured in 
hippocampal extracts but no overall changes in concentration were 
observed (p > 0.05). Cytokines and markers of activated microglia 
and astrocytes were quantified by ELISA. Data were analysed using 
one-way ANOVA with post hoc Tukey analysis. Error bars represent 
SEM
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We also measured two independent markers of tissue oxy-
genation, VEGF and the ratio of MAG:PLP, based on bio-
chemical assays recently developed in postmortem human 
brain tissue [55, 56]. The level of VEGF (F(3, 54) = 0.24, 
p = 0.87), a marker of ischaemia, and the ratio of MAG:PLP 
(F(3, 54) = 2.36, p = 0.083), a marker of tissue oxygenation 
that is lowered as a result of reduced perfusion, were both 
unaltered in the hippocampus across WT and treated Tg 
mice (Supplementary Fig. 7, online resource).
DIZE prevented the onset of cognitive impairment 
and amyloid pathology when delivered 
to asymptomatic (young) Tg2576 mice
In Experiment 4, contact times (Supplementary Table 4, 
online resource) and DR scores (Fig.  6a) revealed that 
9–10-month-old Tg-V and Tg-DIZE mice were able to dis-
criminate objects in novel locations (i.e. were unimpaired) 
prior to treatment (ps > 0.9). At 12–13 months of age, when 
re-tested, Tg-V mice were impaired in the OiP task compared 
to baseline scores (p = 0.001) and compared to WT vehicle 
mice (p = 0.0001). In contrast, Tg2576 mice administered 
Fig. 6  Acute and chronic administration of DIZE prevents the onset 
of cognitive impairment in young pre-symptomatic Tg2576 mice. 
a Associative recognition memory was assessed in younger WT 
(n = 20) and Tg2576 mice (9–12 months of age) that received either 
acute (10 days; n = 17) or chronic (10 weeks n = 11) DIZE administra-
tion. Tg2576 vehicle mice (n = 16) showed an age-dependent impair-
ment in OiP performance (^^^p < 0.001), which was not observed 
in either the acute or chronic DIZE-administered Tg2576 mice 
(ps > 0.05). Tg2576 vehicle mice were also impaired compared to 
WT vehicle (***p < 0.001), Tg2576 acute (•••p < 0.001) and Tg2576 
chronic DIZE administered mice (+++p < 0.001). b–d Aβ levels were 
quantified by ELISA. Soluble Aβ40 level was reduced in both chronic 
(*p < 0.05) and acute DIZE-administered Tg2576 mice (**p < 0.01) 
compared to Tg2576 vehicle mice. Soluble Aβ43 was reduced in 
Tg2576 mice that received acute DIZE administration (*p < 0.05) 
compared to Tg2576 vehicle mice. e–g ACE2 and ACE1 activities 
were determined by enzyme activity assays. ACE2 activity was sig-
nificantly increased in the hippocampus of Tg2576 mice administered 
DIZE either acutely (**p < 0.01) or chronically (p < 0.05) compared 
to WT vehicle mice. Despite a numerical reduction in ACE1 activ-
ity in DIZE administered mice, no significant changes were reported, 
p > 0.05; however, the ratio of ACE2:ACE1 was significantly 
increased in Tg-chronic mice compared to WT vehicle (*p < 0.05). h 
IL-1β level was increased in Tg2576 vehicle mice compared to WT 
vehicle controls (***p < 0.001) but was significantly reduced after 
acute (*p < 0.05) and chronic (**p < 0.01) DIZE administration in 
Tg2576 mice compared to Tg vehicle mice. Behavioural data were 
analysed using mixed measures ANOVA. Significant interactions 
were further analysed by tests for simple main effects with Bonferroni 
corrections for multiple comparisons. ACE2 and IL-1β analyses were 
performed using one-way ANOVA with post hoc Tukey analysis. 
Amyloid analysis was performed using non-parametric Kruskal–Wal-
lis one-way ANOVA with multiple comparisons. Error bars represent 
the SEM
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DIZE over a 10-week period starting at 9–10 months of age 
(asymptomatic) (Tg-DIZE chronic) (p = 0.0001) and Tg2576 
mice administered DIZE for 10 days at 12–13 months of age 
(impaired) (Tg-DIZE acute) (p = 0.001) both performed sig-
nificantly better than Tg-V mice and were indistinguishable 
from WT-V controls mice (ps > 0.1).
In 12–13-month-old Tg-V mice, soluble Aβ levels 
were considerably higher than insoluble Aβ. Soluble 
Aβ40 (H(2) = 8.07, p = 0.018) and Aβ43 (H(2) = 7.97, 
p = 0.019) level significantly differed in chronic and acute 
DIZE-treated mice compared to Tg-V (Fig. 6b–d). Post 
hoc Dunn’s analysis confirmed that soluble hippocampal 
Aβ40 was significantly reduced in both chronic (51.81%) 
(p = 0.035) and acute (48.93%) (p = 0.007) DIZE-treated 
mice compared to Tg-V. Soluble hippocampal Aβ43 was 
significantly reduced in acutely treated Tg2576 mice 
compared to vehicle controls (52.07%) (p = 0.014) and 
numerically reduced by 41.88% in chronic-treated mice 
(p = 0.44). Soluble Aβ42 was numerically reduced in 
acute-treated (43.25%) (p = 0.41) and chronic-treated 
(28.25%) (p = 0.89) mice compared to Tg-V but due to 
variability between individual mice, the difference was not 
statistically significant. All percentage changes in acute 
and chronic DIZE mice are shown in detail in Supplemen-
tary Table 5, online resource.
Hippocampal ACE2 activity was significantly higher 
in Tg-DIZE mice after acute (p = 0.010) and chronic 
(p = 0.013) administration compared to WT-V (Fig. 6e). 
As previously found in older mice, ACE1 was incremen-
tally reduced in relation to duration of DIZE treatment 
and the ratio of ACE2:ACE1 was significantly higher in 
Tg-DIZE mice compared to WT-V (p < 0.05) (Fig. 6f–g).
Hippocampal IL-1β level was significantly increased 
in Tg-V mice compared to WT-V (p = 0.001) but was 
significantly reduced in Tg2567 mice following both 
chronic (p = 0.007) and acute (p = 0.016) exposure to 
DIZE (Fig. 6h).
Discussion
In the present study, we have shown for the first time that 
DIZE-mediated enhancement of brain ACE2 activity pre-
vented cognitive decline when administered chronically 
to young (9–10 months) asymptomatic Tg25676 mice 
and restored cognitive performance in aged impaired 
(13–15 months old) Tg2576 mice. Restoration of cogni-
tive performance in older mice was associated specifically 
with enhancement of ACE2 activity since DIZE-mediated 
protection was abolished when co-administered with C16, 
an ACE2 inhibitor. DIZE-mediated ACE2 enhancement 
was specifically associated with changes in soluble Aβ, 
rather than plaque-associated insoluble Aβ, within the 
hippocampus. DIZE, via ACE2, also reduced hippocam-
pal levels of the pro-inflammatory mediator IL-1β. We 
found that DIZE restored hippocampal MAS receptor 
expression in Tg2576 mice associated with the evidence 
of ‘activated’ glutamatergic signalling processes. DIZE 
also reinstated the balance of hippocampal RAS activity, 
i.e. elevated ACE2 and reduced ACE1 activity. Together, 
these novel data identify a modifiable pathway that has not 
been previously investigated in a transgenic mouse model 
of Aβ pathology and provide mechanistic insights into a 
potential novel target for therapeutic application in AD.
We have recently shown that the RAS is imbalanced in 
early-stage AD; overactivity of classical RAS and reduced 
activity within regulatory RAS are associated with disease 
pathology in human AD brains [4, 5, 35]. Regulatory RAS 
(rRAS) pathways are responsible for Ang-II metabolism and 
counter-balance the detrimental effects of cRAS [60–62]. 
The Ang-II metabolite, Ang-(1–7), which is the central sig-
nalling peptide in rRAS, is the major angiotensin species in 
the CNS [22, 23] indicating that rRAS pathways likely dom-
inate in the CNS under normal circumstances. Our recent 
findings in postmortem AD brain tissue [35, 36] indicate that 
ACE2 activity was reduced by almost 50% in the mid-fron-
tal cortex in AD [35]. The reduction in ACE2 was strongly 
related to the levels of parenchymal Aβ and tau in contrast 
to a weaker relationship between ACE1 and Aβ, where no 
association with tau was observed [4]. Moreover, in plasma 
samples from AD patients, Ang-(1–7) level was similarly 
found to be reduced and related to cognitive performance 
[63]. Lower levels of Ang-(1–7) were inversely correlated 
with accumulation of hyperphosphorylated tau in a naturally 
occurring accelerated ageing mouse line (SAMP8) and in 
P301S transgenic overexpressing tau mice [64].
The present study importantly demonstrated that ACE2 
enhancement, as a result of peripheral DIZE administration, 
was specifically responsible for improved cognitive perfor-
mance and reduced Aβ pathology in transgenic Tg2576 
mice. DIZE has centrally acting effects indicating that it 
either crosses the blood–brain barrier (BBB) or at least influ-
ences CNS levels of ACE2. DIZE restored cognitive per-
formance in older symptomatic Tg2576 mice and protected 
against cognitive decline in younger pre-symptomatic mice 
if administered for 10 weeks in 9–10-month-old asympto-
matic mice Tg2576 mice or acutely for 10 days in cognitively 
impaired 12–13-month-old mice. Our findings are consistent 
with extensive studies showing cognitive and pathological 
benefits from enhancing either ACE2 activity or boosting 
the levels of Ang-(1–7) in mouse models of stroke (reviewed 
in [65]), chronic cerebral hypoperfusion [66], diabetes [67] 
and in recent mouse models of AD where compounds were 
infused intracerebroventricularly [68, 69]. Interestingly, a 
direct comparison in an experimental rat model of ischemia/
reperfusion injury recently indicated that rRAS activation, 
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by XNT-mediated ACE2 enhancement, was more effective at 
reducing resultant pathology compared to the cRAS blocker 
telmisartan, a prototypical ARB [30]. DIZE has previously 
been shown to protect, following intraperitoneal injection 
for 8 weeks, against cognitive decline and disease-related 
pathology in a non-transgenic D-galactose-ovariectomized 
rat model of AD [39]. This is the first report of similar pro-
tection in an established transgenic model of AD.
Co-administration of DIZE with C16 (an ACE2 inhibitor) 
[46, 70] not only allowed us to confirm the cerebroprotec-
tive effects of DIZE were mediated by ACE2 but allowed 
us to identify ACE2-mediated changes that underpinned 
cognitive protection. For instance, cognitive protection in 
Tg2576 mice was associated with changes in soluble Aβ 
species rather than insoluble Aβ load that presumably reflect 
parenchymal plaque load. It will be important to identify 
age-related changes in the soluble and insoluble pools and 
identify the specific Aβ species and assemblies that are asso-
ciated with ACE2 enhancement and cognitive improvement 
in future studies. Disease pathology and cognitive function is 
impaired in ACE2 knockout mice providing further support 
for a role of ACE2 in AD [71]. DIZE reduced hippocampal 
ACE1 (cRAS) activity in Tg2576 mice, consistent with our 
previous findings of an inverse relationship between ACE1 
and ACE2 in AD human brain tissue [35] and highlights 
that rRAS and cRAS are inter-dependent and co-regulated.
The downstream activation of MasR is the likely mecha-
nism preserving cognitive function and reducing amyloid 
pathology in relation to DIZE administration. Ang-(1–7) 
has been shown to mediate LTP and synaptic plasticity and 
improve cognition in rodents following activation of MasR, 
whereas the protective effects were abolished in MasR KO 
mice [32, 33]. A meta-analysis recently confirmed the pro-
tective role of Ang-(1–7) in cognition [13]. Consistent with 
this, we observed robust MasR expression within the hip-
pocampus and subiculum in WT mice, as previously shown 
[31], but found that the expression of MasR was reduced 
in Tg2576 mice (revealed by IHC and ELISA measure-
ment). Importantly, DIZE restored the expression of MasR 
in Tg2576 mice within hippocampal synaptosomal extracts. 
In contrast, the expression of a related alternative rRAS 
receptor, IRAP, which is downstream of Ang-II metabo-
lism and also enhances cognitive function and LTP [34, 72] 
remained unchanged. We also found evidence of increased 
hippocampal expression of a subset of glutamate receptors 
and signalling pathways, specifically NR2B receptor and 
ERK, which influence performance on the OiP task perfor-
mance in normal mice [51, 73]. Activation of ERK, which 
is downstream of NMDA receptor activity, plays a role in 
regulating memory processes [74]. Deficiencies in synaptic 
NMDA NR2B subunit phosphorylation and downstream 
ERK signalling have previously been associated with behav-
ioural deficits in Tg2576, APP23 and 3xTg mice, due in part 
to the effects of excessive Aβ [75–77]. We have previously 
shown that changes in the ratio of total:phosphorylated ERK, 
specifically within synaptosomes, is associated with OiP 
performance in PDAPP mice [51]. These data indicate that 
localised changes in synaptosome ERK signalling observed 
in the DIZE-administered mice are likely to be indicative of 
increased signalling through the NR2B receptor. Interest-
ingly, we observed similar changes in ERK phosphorylation 
in WT mice suggesting that DIZE activates hippocampal 
glutamate signalling in non-diseased mice, i.e. during nor-
mal ageing. Future studies should address whether DIZE 
promotes synaptic and cognitive processes in aged WT mice.
We explored the possible mechanisms that might be 
associated with DIZE-mediated reduction in disease-
related pathology and improved cognition in Tg2576 mice. 
Overactivation of cRAS is associated with oxidative stress, 
inflammation, and vascular dysfunction that are likely to 
contribute to disease pathology and cognitive impairment 
in AD (reviewed in [2]). Of the four cytokines studied (IL-
1β, IL-6, IL-10 and TNF-α), we found that hippocampal 
IL-1β, elevated in Tg2576 mice, was lower and comparable 
to WT levels following DIZE treatment. As for soluble Aβ, 
reduced IL-1β was specific to ACE2 enhancement (i.e. the 
effect was not observed in DIZE + C-16 mice) and was spe-
cifically associated with restoration and protection against 
cognitive decline. IL-1β is a pro-inflammatory cytokine that 
is elevated in AD (reviewed in [78]) and has previously been 
shown to impair LTP and learning and memory performance 
in rodents [79, 80]. Signalling through the MasR (by Ang-
(1–7)) exerts anti-inflammatory effects, including reducing 
IL-1β mRNA levels in cultured microglia [81], which could 
provide an explanation for the observed protective effects 
of DIZE. RAS activity, particularly cRAS activation, has 
also been proposed as an important ‘switch’ in promoting 
a pro-inflammatory M1 state, whilst rRAS activity favours 
an immune-suppressive ‘phagocytic’ M2 phenotype [82], 
which could provide a mechanistic explanation for the 
removal of Aβ [83, 84].
Whilst an attractive hypothesis, our analysis has failed to 
detect any significant changes in two independent markers of 
microglial activation (CD68 and IBA1)—a major source of 
IL-1β. However, a more comprehensive analysis of different 
sub-types of microglial activation markers (particularly mark-
ers of M1/M2 phenotype) is required. Comprehensive analy-
sis of these inflammatory markers in WT mice would also 
provide additional insight into the role of DIZE in mediating 
cerebroprotection in healthy aged mice and should be a focus 
of future studies. Astrocytes were constitutively activated in 
Tg-2576 mice and remained activated in the presence of both 
DIZE and DIZE + C16 indicating that astrocyte activation is 
unlikely to contribute to the observed cognitive protection in 
Tg2576 mice at least at this age. The protective effect of DIZE 
was also not associated, again somewhat surprisingly, given 
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the role of RAS in vaso-modulation and blood pressure, with 
changes in the expression of markers of brain tissue perfu-
sion, VEGF and MAG:PLP (as reviewed in [85]) but this is 
consistent with our findings of unchanged MABP throughout 
the study. Given the recent evidence that RAS-targeting ARBs 
and ACE-Is, associated with reduced incidence and delayed 
onset of cognitive decline in AD patients, are associated with 
reduced tau pathology and lower CSF tau level [14, 86, 87], 
as well as the ability of the ARB losartan to reverse Ang-
II-mediated tau phosphorylation in aged rodents [8], further 
studies should address whether DIZE also modifies disease-
related tau modifications in relation to cognitive decline.
Despite the highly probable involvement of the rRAS path-
way in mediating the protective effects of DIZE, we should 
acknowledge that we did not find an increase in Ang-(1–7) 
levels in DIZE-treated mice. This may be due to inherent tech-
nical difficulties in measuring the level of Ang-(1–7) within 
brain tissue due to low expression and the short half-life of 
the peptide; however, it could also indicate the involvement 
of other rRAS peptides, such as angiotensin-(1-9), that could 
also potentially activate MasR but which were not measured 
in this study. Additionally, DIZE-mediated ACE2 activity 
could act independently of or in combination with rRAS. For 
instance, ACE2 converts Aβ43, an early-depositing species 
of Aβ that has been postulated to be an important seed for 
parenchymal plaque growth and is elevated in AD [88], to a 
less toxic Aβ species via sequential cleavage of Aβ43 to Aβ42 
followed by ACE1-mediated cleavage to the less toxic Aβ40 
[89]. Thus, DIZE-mediated protection might help promote 
clearance of this highly amyloidogenic early-depositing form 
of Aβ. Further studies are, therefore, required to determine the 
precise pathway/s that underly the protective effects of DIZE 
before we can begin to translate these promising preclinical 
findings into the clinic. Given the established influence of 
gender on RAS activation [90–92], particularly in post-men-
opausal females, it will also be important to determine if the 
effects of DIZE are replicated in female mice to inform which 
patient groups are likely to benefit from rRAS intervention.
Collectively these data indicate the potent cognitive 
and pathological benefits following DIZE-mediated ACE2 
enhancement in a Tg2576 mouse model of AD. Our findings, 
together with recent data from postmortem brain tissue, reaf-
firm the importance of the angiotensin hypothesis in AD and 
indicate that activation of the regulatory ACE2/Ang-(1–7)/
MasR rRAS pathway, which works to downregulate the 
cRAS pathway whilst directly boosting memory and learn-
ing, provides an exciting, alternative and novel therapeutic 
target for potential treatment in AD.
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